Oxford BioMedica is a prominent gene and cell therapy company that is devoted to finding cures for critical ailments. The company has pioneered a dominant lentiviral vector delivery platform called LentiVector®, through which it creates in vivo and ex-vivo treatments in-house and with partners. With a remarkable portfolio of gene and cell therapy products specializing in oncology, ophthalmology, and CNS disorders, the company has established itself as a significant player in this field.